CYP7B1 and Parkinson disease: Furthermore, in vivo studies on the effect of voriconazole, in the presence or absence of 7α,26-diHC, on α-synuclein-injected rodents and/or on 6-hydroxydopamine-injected rodents would further indicate whether voriconazole and/or other azole CYP7B1 inhibitors could increase the number of mDA neurons in vivo and whether they could constitute a potential treatment strategy for PD.